UA70351C2 - Method for producing lyophilisates with improved dmethod for producing lyophilisates with improved dissolution rate and particle-free reconstitution (issolution rate and particle-free reconstitution (variants) variants) - Google Patents

Method for producing lyophilisates with improved dmethod for producing lyophilisates with improved dissolution rate and particle-free reconstitution (issolution rate and particle-free reconstitution (variants) variants) Download PDF

Info

Publication number: UA70351C2
Authority: UA; Ukraine
Prior art keywords: lyophilisates; particle; variants; producing; improved
Prior art date: 1999-01-28

Application number

UA2001085974A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Merck Patent Gmbh Merck Patent

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-28

Filing date

2000-01-26

Publication date

2004-10-15

2000-01-26 Application filed by Merck Patent Gmbh Merck Patent filed Critical Merck Patent Gmbh Merck Patent

2004-10-15 Publication of UA70351C2 publication Critical patent/UA70351C2/uk

Links

239000000243 solution Substances 0.000 description 9
238000000034 method Methods 0.000 description 6
238000002360 preparation method Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
238000001035 drying Methods 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
238000000859 sublimation Methods 0.000 description 3
230000008022 sublimation Effects 0.000 description 3
239000004480 active ingredient Substances 0.000 description 2
-1 alkylene glycols Chemical class 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000002107 myocardial effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
108010083687 Ion Pumps Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
150000003938 benzyl alcohols Chemical class 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
IWXNYAIICFKCTM-UHFFFAOYSA-N cariporide Chemical compound CC(C)C1=CC=C(C(=O)N=C(N)N)C=C1S(C)(=O)=O IWXNYAIICFKCTM-UHFFFAOYSA-N 0.000 description 1
229950008393 cariporide Drugs 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
PFSNEEPXSAWFHI-UHFFFAOYSA-N n-(diaminomethylidene)-2-methyl-5-methylsulfonyl-4-pyrrol-1-ylbenzamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=C(C(=O)N=C(N)N)C(C)=CC(N2C=CC=C2)=C1S(C)(=O)=O PFSNEEPXSAWFHI-UHFFFAOYSA-N 0.000 description 1
FNDLQABGYJQJPH-UHFFFAOYSA-N n-(diaminomethylidene)-3-methylsulfonyl-4-propan-2-ylbenzamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.CC(C)C1=CC=C(C(=O)N=C(N)N)C=C1S(C)(=O)=O FNDLQABGYJQJPH-UHFFFAOYSA-N 0.000 description 1
AJDQRQQNNLZLPM-UHFFFAOYSA-N n-(diaminomethylidene)benzamide Chemical compound NC(N)=NC(=O)C1=CC=CC=C1 AJDQRQQNNLZLPM-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
238000005502 peroxidation Methods 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000019432 tissue death Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B5/00—Drying solid materials or objects by processes not involving the application of heat
- F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
- F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Mechanical Engineering (AREA)
Heart & Thoracic Surgery (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Manufacturing Of Micro-Capsules (AREA)
Waveguide Aerials (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

UA2001085974A 1999-01-28 2000-01-26 Method for producing lyophilisates with improved dmethod for producing lyophilisates with improved dissolution rate and particle-free reconstitution (issolution rate and particle-free reconstitution (variants) variants) UA70351C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19903275A DE19903275A1 (de)	1999-01-28	1999-01-28	Lyophilisate mit verbesserter Rekonstituierbarkeit
PCT/EP2000/000569 WO2000044354A1 (fr)	1999-01-28	2000-01-26	Lyophilisats a reconstitution amelioree

Publications (1)

Publication Number	Publication Date
UA70351C2 true UA70351C2 (en)	2004-10-15

Family

ID=7895601

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2001085974A UA70351C2 (en)	1999-01-28	2000-01-26	Method for producing lyophilisates with improved dmethod for producing lyophilisates with improved dissolution rate and particle-free reconstitution (issolution rate and particle-free reconstitution (variants) variants)

Country Status (21)

Country	Link
US (1)	US6770678B1 (fr)
EP (1)	EP1146863B1 (fr)
JP (2)	JP4562288B2 (fr)
KR (1)	KR20010108136A (fr)
AT (1)	ATE266387T1 (fr)
AU (1)	AU757781B2 (fr)
BR (1)	BRPI0007714B8 (fr)
CA (1)	CA2361237C (fr)
CZ (1)	CZ20012693A3 (fr)
DE (2)	DE19903275A1 (fr)
DK (1)	DK1146863T3 (fr)
ES (1)	ES2220404T3 (fr)
HU (1)	HU226585B1 (fr)
NO (1)	NO331321B1 (fr)
PL (1)	PL351140A1 (fr)
PT (1)	PT1146863E (fr)
RU (1)	RU2225709C2 (fr)
SK (1)	SK10542001A3 (fr)
UA (1)	UA70351C2 (fr)
WO (1)	WO2000044354A1 (fr)
ZA (1)	ZA200107081B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003057650A2 (fr)	2002-01-09	2003-07-17	Emisphere Technologies, Inc.	Polymorphes de 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate de sodium
DE102004045825A1 (de) *	2004-09-22	2006-03-23	Merck Patent Gmbh	Lyophilisat enthaltend N-Diaminomethylen-2-methyl-4,5-di-(methylsulfonyl)-benzamid
US8158152B2 (en) *	2005-11-18	2012-04-17	Scidose Llc	Lyophilization process and products obtained thereby
RU2299063C1 (ru) *	2006-03-03	2007-05-20	Федеральное государственное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии имени Г.Н. Габричевского Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" (ФГУН МНИИЭМ им. Г.Н. Габричевского Роспотребнадзора)	Способ сушки термолабильного биологически активного препарата
AU2009243749B2 (en)	2008-05-09	2013-11-21	Merck Patent Gmbh	Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and beta-cell dysfunction
WO2009152168A2 (fr) *	2008-06-09	2009-12-17	Awd. Pharma Gmbh & Co. Kg	Sels d’acide carboxylique de 2-amino-3-carbéthoxyamino-6-(4-fluoro-benzylamino)-pyridine
US7795263B2 (en) *	2008-07-08	2010-09-14	Wildlife Laboratories, Inc.	Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
TW201920174A (zh) *	2017-09-27	2019-06-01	瑞士商羅氏大藥廠股份有限公司	二氮雜雙環辛烷衍生物之醫藥形式及其製法
CN111556752A (zh) *	2017-12-28	2020-08-18	富士胶片富山化学株式会社	冻干制剂的制造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4002748A (en)	1976-01-19	1977-01-11	Eli Lilly And Company	Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration
JPH07114946B2 (ja) *	1988-10-24	1995-12-13	株式会社奈良機械製作所	難溶性物質の処理方法
US5066647A (en) *	1989-04-20	1991-11-19	Erbamont, Inc.	Cyclophosphamide - alanine lyophilizates
EP0589336B1 (fr) *	1992-09-22	1997-01-08	Hoechst Aktiengesellschaft	Benzoylguanidines, leur procédé de préparation et leur utilisation comme agents antiarrhythmiques
JP2747967B2 (ja) *	1993-07-23	1998-05-06	雪印乳業株式会社	シアル酸粉末
ZA949182B (en) *	1993-12-02	1995-07-26	South African Druggists Ltd	Pharmaceutical composition
DE4430861A1 (de) *	1994-08-31	1996-03-07	Merck Patent Gmbh	Heterocyclyl-benzoylguanidine
RU2105569C1 (ru) *	1995-06-05	1998-02-27	Индивидуальное частное предприятие Фирма "Брынцалов"	Способ получения лекарственной формы противоопухолевого антибиотика
DE19529612A1 (de) *	1995-08-11	1997-02-13	Merck Patent Gmbh	Sulfonyl- oder Sulfinyl-benzoylguanidin-Derivate
RU2111426C1 (ru) *	1995-11-03	1998-05-20	Государственный научный центр вирусологии и биотехнологии "Вектор"	Способ лиофильной сушки биопрепарата
JPH09183729A (ja) *	1995-12-29	1997-07-15	Meiji Milk Prod Co Ltd	凍結乾燥ウラシルを含有する抗腫瘍医薬組成物

1999
- 1999-01-28 DE DE19903275A patent/DE19903275A1/de not_active Withdrawn
2000
- 2000-01-26 US US09/889,930 patent/US6770678B1/en not_active Expired - Lifetime
- 2000-01-26 WO PCT/EP2000/000569 patent/WO2000044354A1/fr not_active Ceased
- 2000-01-26 CZ CZ20012693A patent/CZ20012693A3/cs unknown
- 2000-01-26 EP EP00906226A patent/EP1146863B1/fr not_active Expired - Lifetime
- 2000-01-26 PL PL00351140A patent/PL351140A1/xx unknown
- 2000-01-26 BR BRPI0007714A patent/BRPI0007714B8/pt not_active IP Right Cessation
- 2000-01-26 AU AU27986/00A patent/AU757781B2/en not_active Expired
- 2000-01-26 PT PT00906226T patent/PT1146863E/pt unknown
- 2000-01-26 HU HU0105493A patent/HU226585B1/hu not_active IP Right Cessation
- 2000-01-26 KR KR1020017009423A patent/KR20010108136A/ko not_active Ceased
- 2000-01-26 UA UA2001085974A patent/UA70351C2/uk unknown
- 2000-01-26 CA CA002361237A patent/CA2361237C/fr not_active Expired - Lifetime
- 2000-01-26 JP JP2000595658A patent/JP4562288B2/ja not_active Expired - Lifetime
- 2000-01-26 RU RU2001122707/15A patent/RU2225709C2/ru active
- 2000-01-26 AT AT00906226T patent/ATE266387T1/de active
- 2000-01-26 DE DE50006404T patent/DE50006404D1/de not_active Expired - Lifetime
- 2000-01-26 ES ES00906226T patent/ES2220404T3/es not_active Expired - Lifetime
- 2000-01-26 DK DK00906226T patent/DK1146863T3/da active
- 2000-01-26 SK SK1054-2001A patent/SK10542001A3/sk unknown
2001
- 2001-07-27 NO NO20013703A patent/NO331321B1/no not_active IP Right Cessation
- 2001-08-27 ZA ZA200107081A patent/ZA200107081B/xx unknown
2010
- 2010-06-02 JP JP2010126408A patent/JP2010264249A/ja active Pending

Also Published As

Publication number	Publication date
EP1146863B1 (fr)	2004-05-12
HUP0105493A3 (en)	2006-07-28
SK10542001A3 (sk)	2002-01-07
BR0007714B1 (pt)	2014-09-30
ZA200107081B (en)	2003-02-26
CA2361237C (fr)	2008-07-15
DE50006404D1 (de)	2004-06-17
CA2361237A1 (fr)	2000-08-03
PT1146863E (pt)	2004-10-29
CZ20012693A3 (cs)	2002-01-16
DK1146863T3 (da)	2004-08-30
WO2000044354A1 (fr)	2000-08-03
NO331321B1 (no)	2011-11-21
HUP0105493A2 (en)	2002-06-29
AU2798600A (en)	2000-08-18
JP2010264249A (ja)	2010-11-25
PL351140A1 (en)	2003-03-24
ES2220404T3 (es)	2004-12-16
AU757781B2 (en)	2003-03-06
BRPI0007714B8 (pt)	2021-05-25
NO20013703D0 (no)	2001-07-27
JP4562288B2 (ja)	2010-10-13
ATE266387T1 (de)	2004-05-15
NO20013703L (no)	2001-07-27
KR20010108136A (ko)	2001-12-07
JP2002535089A (ja)	2002-10-22
HU226585B1 (en)	2009-04-28
RU2225709C2 (ru)	2004-03-20
EP1146863A1 (fr)	2001-10-24
US6770678B1 (en)	2004-08-03
BR0007714A (pt)	2001-11-27
DE19903275A1 (de)	2000-08-03

Publication	Publication Date	Title
JP2010264249A (ja)	2010-11-25	改善された再生能を有する凍結乾燥体
US9651305B2 (en)	2017-05-16	Lyophilization system and method
CA2234140C (fr)	2004-10-26	Formulation pharmaceutique lyophilisee stable
Izutsu et al.	1994	Physical stability and protein stability of freeze-dried cakes during storage at elevated temperatures
BRPI0307802B1 (pt)	2018-11-27	formulação farmacêutica compreendendo temozolomida, processo para a produção da mesma, bem como artigo fabricado contendo pó liofilizado compreendendo temozolomida
CN101683522A (zh)	2010-03-31	新的无白蛋白的因子ⅷ制剂
HU221428B (en)	2002-10-28	Lyophilized compositions containing ifosfamide and urea and process for production of them
BRPI0719096A2 (pt)	2013-12-03	Formulação parenteral estavel contendo uminibidor de rsv de uma estrutura de benzodiazepina
EP0782850A1 (fr)	1997-07-09	Preparation lyophilisee permettant d'obtenir une composition pharmaceutique a base d'eau se transformant de maniere reversible en gel sous l'effet de la chaleur
JP2023116657A (ja)	2023-08-22	安定な滅菌性且つ結晶性ｏ－アセチルサリチル酸（アスピリン）のバイアル内堆積物
JP2002535089A5 (fr)	2010-02-04
US4963551A (en)	1990-10-16	Stable lyophilized form of (S)-(+)-bis-4,4'-(1-methyl-1,2-ethanediyl)2,6-piperazinedione and solutions thereof
JPH07196517A (ja)	1995-08-01	安定な凍結乾燥済みチオテパ組成物
SK283137B6 (sk)	2003-03-04	Farmaceutické kompozície na liečbu poruchy agregácie krvných doštičiek a spôsob jej prípravy
JP2011137048A (ja)	2011-07-14	新たな用途の薬学的調製物およびその調製物を製造するためのプロセス
JP2003527207A (ja)	2003-09-16	リネゾリド静脈内溶液用容器
JPS61171421A (ja)	1986-08-02	安定なプロスタグランジンｅ類製剤の製造方法
MXPA01007576A (en)	2002-05-09	Lyophilisates with improved reconstitutibility
PT89301B (pt)	1995-07-03	Processo para a preparacao de composicoes aquosas que contem um derivado do acido piperridinil-ciclo-pentil-heptenoico
JP3028298B2 (ja)	2000-04-04	経口用トロンビン製剤
RU2232573C1 (ru)	2004-07-20	Способ получения водного раствора викасола
RU94030750A (ru)	1996-09-27	Способ получения комбинированной лекарственной формы антибиотиков пенициллинового ряда
GB2271281A (en)	1994-04-13	Stabilised cyclophosphamide compositions
JPH02101014A (ja)	1990-04-12	１−〔（４´‐ヒドロキシ‐２´‐ブテノキシ）メチル〕‐２‐ニトロイミダゾールの凍結乾燥製剤の製造方法